We are live on ! Find out more
SCM

Stonepine Capital Management Portfolio holdings

AUM $250M
1-Year Est. Return 77.6%
This Fund
S&P 500
This Quarter Est. Return
-2.81%
1 Year Est. Return
+77.6%
3 Year Est. Return
+198.76%
5 Year Est. Return
+226.15%
10 Year Est. Return
+1,976.54%
AUM
$170M
AUM Growth
-$15.5M
Cap. Flow
-$8.11M
Cap. Flow %
-4.78%
Top 10 Hldgs %
77.17%
Holding
32
New
5
Increased
6
Reduced
10
Closed
10

Top Buys

1
PCRX icon
Pacira BioSciences
PCRX
+$15.1M
2
APEN
Apollo Endosurgery, Inc.
APEN
+$12.5M
3
BSTC
BioSpecifics Technologies Corp.
BSTC
+$7.25M
4
CORV
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
+$4.32M
5
OXFD
Oxford Immunotec Global PLC Ordinary Shares
OXFD
+$2.64M

Top Sells

1
VCEL icon
Vericel Corp
VCEL
+$7.69M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$6.44M
3
ALR
Alere Inc
ALR
+$5.02M
4
DRRX
DURECT Corp
DRRX
+$4.96M
5
CUTR
Cutera, Inc.
CUTR
+$4.53M

Sector Composition

1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VIVE
1
DELISTED
VIVEVE MED INC
VIVE
$20.2M 11.89%
3,850
– –
ENTA icon
2
Enanta Pharmaceuticals
ENTA
$400M
$18.3M 10.76%
390,000
-102,265
-21% -$4.11M
PCRX icon
3
Pacira BioSciences
PCRX
$1.01B
$14.1M 8.3%
+375,200
New +$15.1M
SCTL
4
DELISTED
Societal CDMO, Inc. Common Stock
SCTL
$13.1M 7.71%
1,623,237
-416,844
-20% -$2.85M
NVLN
5
DELISTED
Novelion Therapeutics Inc. Common Shares
NVLN
$12.8M 7.57%
1,826,364
-26,031
-1% -$209K
BDSI
6
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$11.4M 6.73%
3,867,400
+389,727
+11% +$1.19M
APEN
7
DELISTED
Apollo Endosurgery, Inc.
APEN
$11.1M 6.52%
+2,364,707
New +$12.5M
AVDL
8
DELISTED
Avadel Pharmaceuticals
AVDL
$10.3M 6.1%
985,210
+237,347
+32% +$2.27M
ISEE
9
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$9.83M 5.8%
3,487,209
-88,980
-2% -$240K
BSTC
10
DELISTED
BioSpecifics Technologies Corp.
BSTC
$9.83M 5.8%
211,370
+151,492
+253% +$7.25M
CPIX icon
11
Cumberland Pharmaceuticals
CPIX
$102M
$8.98M 5.29%
1,272,191
+163,024
+15% +$1.13M
CORV
12
DELISTED
Correvio Pharma Corp. Ordinary Shares (Canada)
CORV
$6.11M 3.6%
2,866,785
+1,271,236
+80% +$4.32M
VCEL icon
13
Vericel Corp
VCEL
$2.38B
$5.85M 3.45%
975,711
-2,004,859
-67% -$7.69M
VNDA icon
14
Vanda Pharmaceuticals
VNDA
$327M
$5.37M 3.17%
300,000
-385,086
-56% -$6.44M
CTIC
15
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.17M 1.87%
993,000
-1,291,381
-57% -$4.31M
VCYT icon
16
Veracyte
VCYT
$4.72B
$2.89M 1.71%
330,000
-534,695
-62% -$4.35M
OXFD
17
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$2.73M 1.61%
+162,286
New +$2.64M
ICPT
18
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.08M 0.64%
+18,600
New +$2M
CASM
19
DELISTED
CAS Medical Systems, Inc.
CASM
$748K 0.44%
812,718
-87,648
-10% -$89.8K
TRIB
20
Trinity Biotech
TRIB
$6.79M
$688K 0.41%
24,534
-37,865
-61% -$1.06M
ALIM
21
DELISTED
Alimera Sciences
ALIM
$644K 0.38%
31,815
+19,493
+158% +$417K
CBMX
22
DELISTED
CombiMatrix Corporation
CBMX
$475K 0.28%
+63,283
New +$429K
AMRN
23
Amarin Corp
AMRN
$292M
– –
-3,750
Closed -$302K
ASRT
24
DELISTED
Assertio
ASRT
– –
-2,110
Closed -$1.36M
CDNA icon
25
CareDx
CDNA
$2.05B
– –
-190,909
Closed -$212K
1
2

Similar funds

BIA
Bigelow Investment Advisors Portland, Maine $250M AUM 19.33% 1-Year Est. Return
TGP
TMT General Partner Hong Kong $250M AUM 6.05% 1-Year Est. Return
ER
EVR Research Richmond, Virginia $250M AUM 41.5% 1-Year Est. Return
FDDB
Fidelity D&D Bancorp Dunmore, Pennsylvania $249M AUM 18.9% 1-Year Est. Return
VM
VPR Management Houston, Texas $250M AUM 34.13% 1-Year Est. Return
PF
Parker Financial Silverdale, Washington $250M AUM 14.69% 1-Year Est. Return
SCM
Step Capital Management Singapore $249M AUM
CWM
Chicago Wealth Management Chicago, Illinois $251M AUM 45.31% 1-Year Est. Return

Stonepine Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, Stonepine Capital Management held 32 positions worth $170M, down 8.4% from $185M the previous quarter. Its ten largest holdings account for 77% of the portfolio.

Stonepine Capital Management withdrew a net $8.11M in Q3 2017, closing 10 positions and reducing 10 holdings. Its most notable exit was Alere Inc, an estimated $5.02M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Stonepine Capital Management opened a new position in Pacira BioSciences worth $14.1M.

  • Stonepine Capital Management's largest Q3 2017 buy was Pacira BioSciences: 375,200 shares worth $14.1M.
  • Stonepine Capital Management added most to BioSpecifics Technologies Corp. in Q3 2017, an estimated $7.25M increase.
  • Stonepine Capital Management's biggest Q3 2017 reduction was Vericel Corp, cutting an estimated $7.69M.
  • Stonepine Capital Management fully exited Alere Inc in Q3 2017, selling an estimated $5.02M.
  • Stonepine Capital Management's ten largest holdings make up 77% of its $170M portfolio in Q3 2017.
  • Stonepine Capital Management opened 5 new positions and closed 10 in Q3 2017.
  • Stonepine Capital Management's portfolio value fell 8.4% quarter-over-quarter to $170M.

Based on Stonepine Capital Management's 13F filing for Q3 2017, filed 13 Nov 2017.